Plausible ergogenic effects of vitamin D on athletic performance and recovery

Dylan T. Dahlquist, Brad P. Dieter and Michael S. Koehle

Abstract

The purpose of this review is to examine vitamin D in the context of sport nutrition and its potential role in optimizing athletic performance. Vitamin D receptors (VDR) and vitamin D response elements (VDREs) are located in almost every tissue within the human body including skeletal muscle. The hormonally-active form of vitamin D, 1,25-dihydroxyvitamin D, has been shown to play critical roles in the human body and regulates over 900 gene variants. Based on the literature presented, it is plausible that vitamin D levels above the normal reference range (up to 100 nmol/L) might increase skeletal muscle function, decrease recovery time from training, increase both force and power production, and increase testosterone production, each of which could potentiate athletic performance. Therefore, maintaining higher levels of vitamin D could prove beneficial for athletic performance. Despite this situation, large portions of athletic populations are vitamin D deficient. Currently, the research is inconclusive with regards to the optimal intake of vitamin D, the specific forms of vitamin D one should ingest, and the distinct nutrient-nutrient interactions of vitamin D with vitamin K that affect arterial calcification and hypervitaminosis. Furthermore, it is possible that dosages exceeding the recommendations for vitamin D (i.e. dosages up to 4000-5000 IU/day), in combination with 50 to 1000 mcg/day of vitamin K1 and K2 could aid athletic performance. This review will investigate these topics, and specifically their relevance to athletic performance.

Keywords: Vitamin D, Performance, Skeletal muscle, Vitamin K, Dosage, Athlete, Testosterone, Hormones, Recovery

Introduction

Vitamin D, a fat-soluble vitamin, was first discovered in cod liver oil [1] and has since been identified as an essential vitamin, acting as a precursor steroid to a host of metabolic and biological processes. Once converted into its biologically-active form, 1,25-dihydroxyvitamin D [2], it regulates the expression of over 900 gene variants [3]. These gene expressions have been shown to have significant impact on a wide variety of health and performance-related variables, such as exercise-induced inflammation, tumour suppressor genes, neurological function, cardiovascular health, glucose metabolism, bone health and skeletal muscle performance [4–10]. Surprisingly enough, 88.1% of the world’s population has inadequate vitamin D levels [11]. Deficiency has been shown to be linked to a variety of adverse psychological and health outcomes, such as suicidal thoughts [12], depression [13], cognitive decline and neurological impairment [14], and an increased risk of cancer [15]. Furthermore, individuals with inefficient vitamin D stores have an increased risk of bone disorders like spondyloarthitis [16], rickets [1, 17], and fractures due to higher bone resorption from an overproduction of parathyroid hormone (PTH) [18, 19]. Lastly, deficiency has catabolic effects on muscle tissue [20], causes muscle weakness [21], and impairs cross-bridge formation [22], all of which could impair athletic performance. Due to the increase in enzymatic activity of exercise [23], athletes may be as susceptible, if not more susceptible to becoming vitamin D deficient when compared to the general population. A recent meta-analysis pooling 23 studies with 2313 athletes found that 56% of athletes had inadequate vitamin D levels [24]. Because of the high prevalence of vitamin D deficiency [25] and its effects on human physiology, this review is aimed to identify the role of vitamin D in athletic performance (for health related aspects of vitamin D, see [11, 18, 26, 27]). This review will cover how vitamin D is metabolized in the body, its
potential roles in athletic performance, sources of vitamin D, differences between vitamin D₂ and vitamin D₃, optimal levels of vitamin D for athletes, and strategies to achieve these levels and prevent toxicity by nutrient-nutrient interactions.

**Metabolism of vitamin D**

Vitamin D travels in the bloodstream bound to vitamin D-binding proteins [28] and undergoes a three-stage process of key enzymatic reactions [Fig. 1]: 25-hydroxylation, 1α-hydroxylation and 24-hydroxylation [18, 29]. The steroid precursor vitamin D₃ first travels to the liver where it is hydroxylated to 25-hydroxyvitamin D [25(OH)D] by 25-hydroxylase, which is mediated by the cytochrome P450 enzymes, CYP27A1 (in the mitochondria) and CYP2R1 [29]. This 25(OH)D is then hydroxylated by CYP27B1 (1α-hydroxylation) [29]. This final step occurs primarily in the kidney [18], but various other tissues, namely skeletal muscle, have also been shown to express CYP24A1 enzymes, where 25(OH)D becomes the active hormonal form, 1,25-dihydroxyvitamin D [29]. 1,25-dihydroxyvitamin D then interacts with vitamin D receptors (VDR), which are located in almost every tissue in the body [30, 31], and is then transcribed into the cell and binds to vitamin D response elements (VDREs) located in DNA [18]. If 1,25-dihydroxyvitamin D does not interact with VDREs, it is further degraded by CYP24A1 (24-hydroxylase) to the inactive form, calcitriol acid [29].

**Vitamin D and performance**

Vitamin D₃ receptors exist in human skeletal muscle tissue [30, 31], indicating that 1,25-dihydroxyvitamin D has a direct effect on skeletal muscle activity. Research on the muscle effects of vitamin D₃ [32] is limited to diseased populations [20, 33], or healthy untrained adults [34]. Until recently, a few reviews and meta-analyses have shown that increasing serum 25(OH)D levels in a given population have a positive effect on muscle strength, power and mass [33–35] but the only study that examined the effects in athletes [36], had mixed results. In addition, von Hurst and Beck [36] concluded that the optimal intake and serum concentration of 25(OH)D have yet to be identified in the athletic population.

**Maximal oxygen uptake**

Vitamin D receptors (VDR) are present in cardiac muscle and vascular tissue [7], indicating that 1,25-dihydroxyvitamin D might influence maximal oxygen uptake (VO₂max) via the ability to transport and utilize oxygen within the blood to various tissues. Multiple correlative studies showed a positive correlation between VO₂max and serum 25(OH)D concentration in non-athletes [Table 1] [37–39]. However many confounding variables were not addressed, such as concomitant multivitamin [38] and supplement intake [37, 39]. Studies performed in athletes are conflicting. Koundourakis and his colleagues [40] found that there was a significant correlation between 25(OH)D levels and performance parameters in 67 Caucasian male professional soccer players (age 25.6 ± 6.2). A linear relationship was seen between pre- and post- offseason measurements of 25(OH)D and muscle strength indicated by squat jump (SJ), countermovement jump (CMJ), sprinting ability (10- and 20- m sprint) and VO₂max [40]. A more recent publication by Fitzgerald et al. [41], concluded that there was no association between 25(OH)D levels and an individual's

---

*Fig. 1* Metabolism of vitamin D₃ derived from the diet, pharmacological analogs and natural sunlight to the major circulating metabolite of vitamin D (25-hydroxyvitamin D), and subsequently to the active hormonal form, 1,25-dihydroxyvitamin D
VO₂ max in 52 Caucasian competitive ice hockey players [41]. Additionally, the correlation commonly seen between the serum 25(OH)D concentrations and VO₂ max is inversely related to increases in physical activity and training status [39]. Forney and her colleagues [42] recently investigated the association between serum
25(OH)D, VO2max and training status in 39 physically-active college students (20 men, 19 women). They showed that the participants with higher (>35 ng·mL⁻¹) serum 25(OH)D levels had a significantly higher VO2max (+20 %) than the low (<35 ng·mL⁻¹) serum 25(OH)D group [42]. However, this correlation was limited to males only.

Intervention trials in the athletic population are scarce. To our knowledge, only one exists looking at the effects of vitamin D supplementation on VO2max. Jastrzebski [43] performed a single-blinded trial of supplementation with 6000 IU/day of vitamin D₃ versus a placebo during an 8-week training cycle in 14 elite lightweight rowers with sufficient 25(OH)D concentrations (>30 ng/mL). They demonstrated a significantly increase in VO2max (12.1 % and 10.3 %, respectively) and 25(OH)D concentrations by 400 % (~120 ng/mL). The authors concluded that supplementation of vitamin D₃ during the 8-week training period significantly improved aerobic metabolism in the elite rowers [43]. Further research is needed to test whether an ergogenic effect exists in athletes who are severely deficient in serum 25(OH)D, and if supraphysiologically dosages of vitamin D₃, such as that used by Jastrzebski, have an ergogenic effect in vitamin D replete athletes in other sport disciplines.

The specific mechanism by which increased levels of 25(OH)D affect VO2max remains unclear [39], however this phenomenon could be due to the fact that the CYP enzymes that activate vitamin D₃ into 1,25-dihydroxyvitamin D₃ have heme-containing proteins [44] and could potentially affect the binding affinity of oxygen to hemoglobin.

Recovery
The ability to recover rapidly is important for athletes to train at high intensities more frequently. Human skeletal muscle tissue responds to training stimuli and/or tissue damage through remodeling [45–47]. During recovery, 1,25-dihydroxyvitamin D increases the myogenic differentiation and proliferation [48] and down-regulates myostatin, an inhibitory regulator of muscle synthesis of C2C12 myoblasts in culture [49]. Stratos and colleagues [50] showed this marked increase in skeletal muscle regeneration in a crushed soleus muscle (in vivo) of 56 male Wistar rats (300 to 325 g body weight), after a supraphysiologically dose of ~100,000 IU of vitamin D. They [50] separated rats into a high (332,000 IU/kg) and low (33,200 IU/kg) dose groups and examined recovery response times to the crushed soleus muscle. When compared to the low dose group, the high dose group had a significant attenuation of apoptosis four days post-injury, indicative of an increase in cellular matrix proteins [50]; which is crucial for skeletal tissue repair [51]. This increase in cellular turnover rate led to the enhanced recovery time, an increase in tetanic force production (only 10 % lower than the non-injured limb), and an increase in twitch force when compared to the control group [50]. As murine models display regenerative capacities that exceed those of humans, it is important to note the limitations of extending the aforementioned findings to humans; however, the finding that vitamin D supplementation enhances the recovery in peak isometric force shortly after intense exercise was recently supported in much lower doses in modestly-active humans [52].

In a randomized, double-blind, placebo-controlled study, Barker et al. [52] demonstrated that 4000 IU/day for 35 days of vitamin D in healthy and moderately active adults attenuated the inflammatory biomarkers alanine (ALT) and aspartate (AST) immediately following 10 sets of 10 repetitions of peak isometric force eccentric-concentric jumps. Furthermore, although peak power output decreased in both the groups, the supplementation group only decreased by 6 %, while the placebo group’s power decreased by 32 % immediately post-exercise [52]. This discrepancy persisted at 48 h [52]. Further research examining higher dosages would be warranted to determine if recovery and power output are improved to a greater degree [Table 2].

Force and power production
Vitamin D₃ has also been shown to increase force and power output of skeletal muscle tissue [19], perhaps through the sensitization of calcium binding sites on the sarcoplasmic reticulum, leading to an enhanced crossbridge cycling and muscular contraction [53]. There is further evidence that vitamin D₃ might also potentially increase both size and number of type II muscle fibers [20, 54, 55]. These findings have only been supported in mobility-limited elderly (≥65 years old) women [55], and have yet to be tested in the athletic population. On the other hand, increases in force and power production have been studied in athletes with positive results during a randomized placebo-controlled study in 10 male professional soccer players [56]. After an 8-week long intervention of either receiving 5000 IU/day of vitamin D₃ or a placebo, the vitamin D₃ group had a significant increase in serum 25(OH)D levels and a significant improvement in both their 10-m sprint times and vertical jump when compared to the placebo group [56]. Confounding variables were well-controlled, in that the authors instructed the athletes to maintain current nutritional intake, and excluded any athlete who was taking a multivitamin, vitamin D, fish oil and/or were regular sunbed users or who just returned from a vacation in a sunlight enriched climate. However, other studies have shown no significant benefit of vitamin D supplementation in athletes with moderately deficient or adequate levels [10, 41, 42], indicating that these
Vitamin D correlation and intervention studies on force & power production

Author | Reference | Population | Subjects/Specimens | Type of Study | Intervention | Duration | Results
--- | --- | --- | --- | --- | --- | --- | ---
Garcia et al. 2013 | [48] | Human - Ex Vivo | Human Myoblasts | In Vitro | C2C12 Myoblasts treated with 100 nM of 1,25-D3 or Placebo | 1, 4, and 10 Days | ↑ in Myogenic Differentiation & Proliferation
Garcia et al. 2011 | [49] | Human - Ex Vivo | Human Myoblasts | In Vitro | C2C12 Myoblasts treated with 100 nM of 1,25-D3 or Placebo | 1, 3, 4, 7, and 10 Days | Down-regulation of Myostatin
Stratos et al. 2013 | [50] | Rat Model | 56 Male Wistar Rats | Intervention - In Vivo | High Dose Group: 332,000 IU/kg, Low Dose Group: 33,200 IU/kg - Regeneration of Crushed Soleus Muscle | 42 Days | High vs Low: (1) ↑ in Apoptosis (2) ↑ in Cellular Matrix Proteins (3) ↑ Tectonic Force Production (4) Enhanced Recovery
Barker et al. 2013 | [52] | Healthy & Active Males | 28 Mode rat ly Active (30-min of exercise 3xWeek) Males (Vitamin D Group Age =30 ± 6, N = 14); (Placebo Group Age =31 ± 5, N = 14) | Intervention - RCT - Placebo + Double Blind | 10 sets of 10reps of peak isometric force jumps 4000 IU of Vitamin D3 or Placebo/Day | 28 Days | Vitamin D vs Placebo: (1) ↓ ALT and AST(2) Less of a ↓ in peak power output

Table 2 Vitamin D in vitro, in vivo and intervention studies on recovery

| Author | Reference | Population | Subjects/Specimens | Type of Study | Intervention | Duration | Results |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Garcia et al. 2013 | [48] | Human - Ex Vivo | Human Myoblasts | In Vitro | C2C12 Myoblasts treated with 100 nM of 1,25-D3 or Placebo | 1, 4, and 10 Days | ↑ in Myogenic Differentiation & Proliferation |
| Garcia et al. 2011 | [49] | Human - Ex Vivo | Human Myoblasts | In Vitro | C2C12 Myoblasts treated with 100 nM of 1,25-D3 or Placebo | 1, 3, 4, 7, and 10 Days | Down-regulation of Myostatin |
| Stratos et al. 2013 | [50] | Rat Model | 56 Male Wistar Rats | Intervention - In Vivo | High Dose Group: 332,000 IU/kg, Low Dose Group: 33,200 IU/kg - Regeneration of Crushed Soleus Muscle | 42 Days | High vs Low: (1) ↑ in Apoptosis (2) ↑ in Cellular Matrix Proteins (3) ↑ Tectonic Force Production (4) Enhanced Recovery |
| Barker et al. 2013 | [52] | Healthy & Active Males | 28 Mode rat ly Active (30-min of exercise 3xWeek) Males (Vitamin D Group Age =30 ± 6, N = 14); (Placebo Group Age =31 ± 5, N = 14) | Intervention - RCT - Placebo + Double Blind | 10 sets of 10reps of peak isometric force jumps 4000 IU of Vitamin D3 or Placebo/Day | 28 Days | Vitamin D vs Placebo: (1) ↓ ALT and AST(2) Less of a ↓ in peak power output |

performance benefits might be limited to individuals with significant vitamin D deficiency [Table 3].

Vitamin D and testosterone

Testosterone is an endogenous hormone important for muscular adaptations to training. Naturally low testosterone levels in young men have been linked to decreases in protein anabolism, strength, beta-oxidation, and an increase in adipose deposition [57]. Thus, athletes endeavour to optimize natural androgenic production. A recent cross-sectional study done on 2299 older men (62 ± 11 years of age) showed that 25(OH)D levels...
correlated with testosterone and androgen levels in men [58]. Low testosterone, or hypogonadism, was identified in 18% of the participants, and these men had significantly lower mean 25(OH)D levels than the rest of the population. Furthermore, only 11.4% of the sample had sufficient levels of vitamin D.

Additionally a 12-month, double-blind, randomized control trial in 54 non-diabetic males demonstrated that the group receiving 3332 IU/day of vitamin D had a significant increase in circulating 25-hydroxyvitamin D, total testosterone, bioactive testosterone, and free testosterone levels [59]. These findings support the notion that elevating 25(OH)D levels may augment testosterone production in non-diabetic male subjects, which indicates that vitamin D supplementation might have ergogenic potential through the enhancement of endogenous testosterone production. More research is required in order to investigate this potential role of vitamin D and testosterone levels in various study populations [Table 4].

The specific mechanism of action of 25(OH)D on testosterone in men could potentially be related to two processes: inhibited testosterone aromatization and enhanced androgen binding. Evidence for both of these mechanisms comes from animal models. Specifically, higher 25(OH)D levels inhibit gonadal aromatization of testosterone in VDR knockout mice [60]. Secondly, VDR and vitamin D metabolizing enzymes have been located in human and rat testis and have been shown to enhance the affinity of androgen binding receptors [57, 61, 62]. This effect increases the rate at which androgens can bind to testosterone-producing glands resulting in higher concentrations of steroid hormones, leading to an increase in skeletal muscle hypertrophy, strength and power output [63, 64].

Sources

Sunlight

Humans acquire vitamin D from two different sources, endogenous production after sun exposure, or via the diet (from food or supplementation). Unlike the metabolism of dietary vitamin D, the synthesis of vitamin D3 by the skin is a non-enzymatic biological process [65]. Once the skin is exposed to the Sun’s ultraviolet B (UVB) radiation, it then converts stored 7-dehydrocholesterol into circulating vitamin D3, 25(OH)D [29] and other isomers [66]. The amount of UVB exposure determines the amount and the specific isomers of vitamin D3 that will form [66, 67]. The recommended dosage of sunlight exposure during the summer is five to 20 min per day to 5.0% of exposed skin at a UVB radiation of 290–315 nm [68, 69] two to three times a week [70]. Additionally, it has been shown that 15 min of adequate (290–315 nm) UVB exposure during the summer months in a bathing suit can produce 10,000 to 20,000 IU of vitamin D3 [71]. However, multiple factors can affect the rate and synthesis of vitamin D3 [Table 5] [25, 66, 72–74].

Diet

Vitamin D derived from diet and supplementation comes in two forms, the plant-based vitamin D2 (ergocalciferol), and the more bioavailable mammal and fish source, vitamin D3 (cholecalciferol) [75]. Vitamin D can be found in various food products [Fig. 2] [76], such as fortified cereals and milk, natural foods like salmon, or through various vitamin D analogues produced synthetically in a laboratory [Table 6] [18, 76]. Both sources are considered prohormone compounds, capable of increasing circulating 25(OH)D, after they have been converted by the enzymatic reactions described earlier.

Dosage for optimal performance

Both D2 and D3 are capable of increasing plasma 25(OH)D concentration, but vitamin D3 might be more effective than vitamin D2 [75, 77, 78]. When compared to vitamin D3, vitamin D2 is less stable, less bioavailable with increasing age, and it has been shown in multiple clinical studies that the amount of vitamin D2 absorbed is significantly lower than with vitamin D3. Furthermore, vitamin D2 has a lower affinity to VDRs [54, 75, 77–79] and a higher rate of deactivation once hydroxylated in

| Author | Reference # | Population | Subjects/specimens | Type of study | Intervention | Duration | Results |
|--------|-------------|------------|--------------------|---------------|--------------|----------|---------|
| Wehr et al. | [53] | Elderly | 2,299 Caucasian Male Subjects (age 52 ± 11) | Cross-sectional | - | - | Positive correlation seen between 25(OH)D levels and Testosterone and Androgen Levels |
| Pilz, Frisch & Koertke | [59] | Healthy Males | 54 Healthy Overweight Males (age range 20–49) | Intervention - RCT | 3332 IU/Day of Vitamin D3 Placebo | 12 Months | Significant ↑ in 25(OH)D, Total Testosterone, Bioactive Testosterone and Free Testosterone Positive relationship between higher |
| Kinuta et al. | [60] | Rat Model | VDR Knockout Mice | Intervention - In Vivo | VDR Knockout Mice - Disruption of VDR gene | - | 25(OH)D levels and inhibition of gonadal aromatization of testosterone |
the kidney due to side-chain variations [77]. Lastly, an epidemiological study during the winter months in Dunedin, New Zealand investigated the effects of 1000 IU/day of either vitamin D$_2$ or vitamin D$_3$ supplementation over a 25-week period in 95 healthy, adult participants (18–50 years old) [78]. The participants who received the vitamin D$_2$ supplement had a larger decrease in serum 25(OH)D (74 nmol/L to 50 nmol/L) levels than those who took vitamin D$_3$ (80 nmol/L to 72 nmol/L) [78]. However, both results show that 1000 IU/day of vitamin D was inadequate to increase serum 25(OH)D concentrations and actually caused a decline with both isoforms.

With vitamin D$_3$ proving more efficacious, the optimal dosage varies depending on the individual and the institution providing the guidelines. The Institute of Medicine (IOM) recommends 400–800 IU/day for children, adults and individuals >70 years of age to maintain serum vitamin D at >50 nmol/L [11, 80, 81]. Alternatively, the Endocrine Society (ES) recommends a slightly higher intake, with dosages of 400–1000 IU/day for infants, 600–1000 IU/day for children, and 1500–2000 IU/day for adults in order to maintain adequate serum vitamin D concentrations of 75 nmol/L [82]. These recommendations correspond with a review in 2004 [83], stating that 70 nmol/L is the lowest desirable serum concentration to prevent adverse health effects. Other recommendations have suggested optimal levels may be 90 to greater than 120 nmol/L [86, 87], based on estimations made from that of levels seen in individuals inhabiting very sunlight-rich environments [84] and/or have shown optimal lower-extremity function [85].

The definitions of hypovitaminosis or hypervitaminosis are more controversial. The IOM defines inadequate stores of 25(OH)D as 30–50 nmol/L, and deficiency as 25(OH)D <30 nmol/L [88], and sets the upper limit of dietary intake of vitamin D to 4000 IU/day [69]. The ES on the other hand, defines vitamin D deficiency at levels of 25(OH)D <50 nmol/L, insufficiency as 25(OH)D between 51 to 74 nmol/L [89], and sets the upper limit of dietary intake of vitamin D to 10,000 IU/day [19]. However, recent reviews have suggested that this is more of a theoretical concern [72, 83, 84, 90]. The optimal vitamin D dosage and level are clearly controversial [88, 91]. Furthermore, the optimal levels needed for athletic performance have not yet been determined. Growing evidence has supported that 600–800 IU/day may not be sufficient for optimal levels of vitamin D, especially for the athletic population [92], since serum 25(OH)D concentrations

| Table 5 Factors affecting the rate and synthesis of endogenously produced vitamin D |
| Seasonal Variations in UVB Exposure |
| Living at Latitudes (~32-42° N or S) That Are Further Away From The Equator |
| Higher Altitudes |
| Cloudy Climates |
| Thick Ozone Layers due to Pollution |
| Darker Skin Pigmentation (higher melanin [natural sun-block] levels) |
| Higher Adipose Tissue (obesity) |
| Older Age |
| Utilization of Sun-block |

Fig. 2 Dietary sources of vitamin D$_3$ and D$_2$ through whole (natural) or fortified food sources
greater than 100 nmol/L have been proposed to be optimal for lower body skeletal muscle function [85] and low vitamin D levels are linked to increased bone turnover, increasing the risk of stress fractures [93]. It has been shown that it takes roughly 2000 to 5000 IU/day of vitamin D from all available sources in order to optimize bone health by maintaining serum 25(OH)D levels of 75 to 80 nmol/L [84, 85, 94, 95]. Furthermore, this dosage would be unattainable from natural UVB exposure during the months of October to April when residing in latitudes of 42.2 to 52° N [96] which is indicated by the high prevalence of vitamin D deficient indoor and outdoor athletes in a multitude of disciplines [24, 97–99]. Lastly, studies that have shown to improve athletic prowess utilize dosages higher than 3000 IU/day, but none have yet to reach levels greater than 100 nmol/L. Thus, it remains unclear, but athletes may benefit from 25(OH)D levels ≥100 nmol/L in order to increase skeletal muscle function and reduce the risk of stress fractures.

However, no study to date has looked at the effects of vitamin D supplementation and skeletal muscle function in the athletic population with 25(OH)D levels of ≥100 nmol/L [36]. Additionally, the previous performance intervention studies presented in this review supplemented with dosages far greater than the recommended dosages of 600–2000 IU/day (e.g., 5000 IU/day of D₃) and 1000 IU/day of vitamin D₃ during the winter months is not enough to prevent a decline in serum 25(OH)D stores [78].

### Toxicity & hypercalcemia

Although it has been reported that vitamin D toxicity might occur with dosages of ≥10,000 IU/day for an extended period [71, 84], producing adverse effects like hypercalcemia, the level of vitamin D causing toxicity is unclear [71, 100], and due to ethical reasons, no prospective studies have analyzed the effect of vitamin D intoxication in humans. Recently, an accidental overdose of 2,000,000 IU of vitamin D₃ in two elderly patients did not cause adverse effects and only elevated blood calcium levels slightly [101]. More importantly, adverse effects have only been reported at serum concentrations of 25(OH)D above 200 nmol/L, which would take daily dosages of 40,000 IU or more of vitamin D to achieve [84], and serum concentrations of 25(OH)D of <140 nmol/L have not been correlated with hypercalcemia. 1,25-dihydroxyvitamin D works synergistically with calcium and allows it to be absorbed from the gastrointestinal tract and stimulates mature osteoblasts to produce receptor activator nuclear factor-kB ligand (RANKL) [102]. RANKL in turn stimulates mineralization and bone resorption via osteoclastogenesis. Increased levels of 25(OH)D can accelerate this process, causing a rise in calcium concentration in the blood, a higher absorption rate of calcium by the kidneys, and could potentially lead to kidney stones and/or potential vascular calcification [103].

### Vitamin K

Any discussion of vitamin D toxicity merits mention of vitamin K. As with calcium, vitamin K works synergistically with vitamin D to regulate bone resorption, activation and distribution [104]. Vitamin K carboxylates the newly-formed osteocalcin proteins that are produced in mature bone cells and are tightly regulated by vitamin D [105]. Once the protein is carboxylated, it interacts with calcium ions in bone tissue [106] and has a significant effect on bone mineralization, formation, the prevention of bone loss, and potentially the stoppage of fractures in women [105, 107–111]. However, when levels of vitamin K are inadequate, the osteocalcin production is not suppressed [109]. This situation facilitates a build-up of uncarboxylated (inactive) osteocalcin proteins in bone, leading to a potential increase in calcium release from bone and the deposition of calcium into soft tissues (causing arterial calcification) [112, 113]. Thus, vitamin D₃ toxicity might occur only in the absence of sufficient vitamin K stores.
Recommended dosages of vitamin K range from 50 mcg to 1000 mcg [108]. However, these recommendations are controversial since vitamin K stores are rapidly depleted without constant supply [114] and like vitamin D, vitamin K also has two variants: K₁ and K₂. Sources of vitamin K can be found in pharmacological analogues and naturally in the diet. Vitamin K₁, the most abundant form found in an individual’s diet [115], is high in green leafy cruciferous vegetables, fruits, various vegetable oils and beans [114]. Vitamin K₂, the more bioavailable form of vitamin K [114], comes in a variety of fish, offal, meat, dairy products, fermented cheese (e.g., blue cheese), and fermented products like natto (fermented soybeans, a Japanese delicacy) [116].

Both forms play different roles in the body [117], but the IOM has set the recommended dietary intake only for the K₁ isofrom (90 mcg/day for women and 120 mcg/day for men), with no upper limit, and has yet to set any dietary recommendation for vitamin K₂ [114]. Specifically, vitamin K₁ has a key role in the carboxylation of various blood clotting proteins, where vitamin K₂ is essential for the carboxylation and activation of osteocalcin and matrix Gla protein (MGP) (an essential protein needed to prevent soft tissue calcification) [118]. More importantly, one of the vitamin K₂ variants, MK-4, is more effective at mitigating osteoclast formation and the negative health effects of vitamin D overdose [114, 115]. Furthermore, 10 mg/day (10,000 mcg) of synthetic vitamin K₁ (phytonadione, sold as Konakion® [119]) has been shown to be beneficial for elite female marathon runners by increasing bone formation and preventing bone loss [120] and mega-doses of 45 mg/day (45,000 mcg) of MK-4 in combination with vitamin D₃ could prevent osteoporosis in postmenopausal women [102, 109]. Thus, although MK-4 might have the greatest effect on carboxylation of osteocalcin, both vitamin K₁ and K₂ interact with each other in order to optimize bone health and are essential to the human body. Further research in athletic populations should focus on the optimal dosage for vitamin D₃ in combination with vitamin K.

Conclusion

In summary, an interesting theme has emerged from animal studies that supraphysiological dosages of vitamin D₃ have potential ergogenic effects on the human metabolic system and lead to multiple physiological enhancements. These dosages could increase aerobic capacity, muscle growth, force and power production, and a decreased recovery time from exercise. These dosages could also improve bone density. However, both deficiency (12.5 to 50 nmol/L) and high levels of vitamin D (>125 nmol/L) can have negative side effects, with the potential for an increased mortality [121]. Thus, maintenance of optimal serum levels between 75 to 100 nmol/L [11, 86] and ensuring adequate amounts of other essential nutrients including vitamin K are consumed, is key to health and performance. Coaches, medical practitioners, and athletic personnel should recommend their patients and athletes to have their plasma 25(OH)D measured, in order to determine if supplementation is needed. Based on the research presented on recovery, force and power production, 4000-5000 IU/day of vitamin D₃ in conjunction with a mixture of 50 mcg/day to 1000 mcg/day of vitamin K₁ and K₂ seems to be a safe dose and has the potential to aid athletic performance. Lastly, no study in the athletic population has increased serum 25(OH)D levels past 100 nmol/L, (the optimal range for skeletal muscle function) using doses of 1000 to 5000 IU/day. Thus, future studies should test the physiological effects of higher dosages (5000 IU to 10,000 IU/day or more) of vitamin D₃ in combination with varying dosages of vitamin K₁ and vitamin K₂ in the athletic population to determine optimal dosages needed to maximize performance.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DTD formulated the idea for the literature review, acquired the research articles, interpreted the literature presented, and drafted the initial manuscript; BD and MSK helped advise the direction of the manuscript, articles, interpreted the literature presented, and drafted the initial manuscript; BD and MSK helped advise the direction of the manuscript, interpreted the literature presented, and drafted the initial manuscript; BD and MSK helped advise the direction of the manuscript, interpreted the literature presented, and drafted the initial manuscript; BD and MSK helped advise the direction of the manuscript, interpreted the literature presented, and drafted the initial manuscript; BD and MSK helped advise the direction of the manuscript, interpreted the literature presented, and drafted the initial manuscript. Each author read and approved the final manuscript prior to submission.

Author details

1 Simon Fraser University, Biomedical Physiology and Kinesiology (BPK), 8888 University Drive – Burnaby, Vancouver, BC V5A 1S6, Canada.
2 University of British Columbia, Vancouver, BC, Canada.
3 Providence Medical Research Center, Providence Sacred Heart Medical Center and Children’s Hospital, Research Discovery Lab, Spokane, WA 99204, USA.

Received: 1 April 2015 Accepted: 9 August 2015
Published online: 19 August 2015

References

1. McCollum E, Simmonds N, Becker J, Shipley P. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem. 1922;1922:293–8.
2. Jones G. Metabolism and biomarkers of vitamin D. Scand J Clin Lab Invest. 2012;72(Suppl 243):7–13.
3. Wang T-T, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, et al. Large-scale in silico and micro-array-based identification of direct 1,25-dihydroxyvitamin D₃ target genes. Mol Endocrinol. 2005;19:2685–95.
4. Smith DT, Broughton KS, Larson-meyer DE. Vitamin D status and biomarkers of inflammation in runners. 2012;3:35–42.
5. Alvarez-Diaz S, Valle N, Garcia JM, Peña C, Freije JMP, Quesada V, et al. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J Clin Invest. 2000;119:2343–58.
6. Dhesi JK, Jackson SHD, Bearne LM, Moniz C, Hurley MV, Swift CG, et al. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing. 2004;33:589–95.
7. Reddy Vanga S, Good M, Howard PA, Vacek JL. Role of vitamin D in cardiovascular health. Am J Cardiol. 2010;106:796–805.
8. Sukumar D, Shapess SA, Schneider SH. Vitamin D supplementation during short-term caloric restriction in healthy overweight/obese older women: effect on glycemic indices and serum osteocalcin levels. Mol Cell Endocrinol. 2015;410:1–5.

9. Schoenmakers I, Francis RM, McCell E, Chadwick T, Goldberg GR, Harle C, et al. Vitamin D supplementation in older people (VOCUS); Study protocol for a randomised controlled intervention trial with monthly oral dosing with 12,000 IU, 24,000 IU or 48,000 IU of vitamin D3; Trials. 2013;14:299.

10. Close GL, Leckey J, Patterson M, Bradley W, Owens DJ, Fraser WD, et al. The effects of vitamin D(3) supplementation on serum total 25(OH)D concentration and physical performance: a randomised dose–response study. Br J Sports Med. 2013;47:692–6.

11. Bendik, I, Friedel A, Roos FF, Weber P, Eggersdorfer M, Vitamin D: a critical and essential micronutrient for human health. Front Physiol. 2014;5:248.

12. Grudet C, Malm J, Westrin A, Brundin L. Suicidal patients are deficient in vitamin D. J Psychiatr Res. 2015;72:150–5.

13. Polak MA, Houghton LA, Reeder AL, Harper ML, Conner TS. Serum 25-hydroxyvitamin D concentrations and depressive symptoms among young adult men and women. Nutrients. 2014;6:4720–30.

14. Chei CL, Raman P, Yin Z-X, Shi X-M, Zeng Y; Matchar DB. Vitamin D levels and cognition in elderly adults in China. J Am Geriatr Soc. 2014;62(11):2125–9.

15. Holick MF. Vitamin D. Its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;92(4–5):29–49.

16. Guillot X, Prati C, Wendling D. Vitamin D and spondyloarthropathy. Expert Rev Clin Immunol. 2014;10:1581–9.

17. Welch TR, Bergstrom WH, Tsang RC. Vitamin D-deficient rickets: the reemergence of a once-conquered disease. J Pediatr. 2000;137:143–5.

18. Bile OD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21:319–29.

19. Ogan D, Pritchett K. Vitamin D and the athlete: risks, recommendations, and benefits. Nutrients. 2013;15:1856–68.

20. Sato Y, Iwamoto J, Kanoko T, Satoh K. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis. 2005;20:187–92.

21. Ringen H, Mikkelsen K, Poulsen L, Hass E, Overbeck S, Andersen H, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int. 2000;66:419–24.

22. Pfeifer M, Begerow B, Minne H. Vitamin D and muscle function. Osteoporo Int. 2002;13:187–94.

23. Macdougall JD, Hicks AL, MacDonald JR, Mckelvie RS, Green HJ, Smith KM. Muscle performance and enzymatic adaptations to sprint interval training. J Appl Physiol. 2006;92:138–42.

24. Farrokh A, Tabasinejad R, Dao D, Peterson D, Ayeni O, Hadioonzadeh M, et al. Low-dose vitamin D prevents muscular atrophy and reduces falls and hip fractures in women after stroke: a randomized controlled trial. Cerebrovasc Dis. 2005;20:187–92.

25. Macdougall JD, Hicks AL, MacDonald JR, Mckelvie RS, Green HJ, Smith KM. Muscle performance and enzymatic adaptations to sprint interval training. J Appl Physiol. 2006;92:138–42.

26. Hossein-nezhad A, Holick MF. Vitamin D for health: a global perspective. Mayo Clin Proc. 2013;88(2):200–5.

27. Schloegl M, Holick MF. Vitamin D and neurocognitive function. Clin Interv Aging. 2014;9:659–68.

28. Holick MF. Vitamin D: evolution, physiological and health perspectives.Curr Drug Targets. 2011;12:4–18.

29. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci. 2004;29:664–70.

30. Bischoff-Hordischek M, Gudat F, Duerkmueller U, Theiler R, Stafelin H, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochim J. 2001;33:19–24.

31. Simpson R, Thomas G, Arnold A. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem. 1985;360:8882–91.

32. Hamilton B. Vitamin D and athletic performance: the potential role of muscle. Asian J Sports Med. 2011;2:11–19.

33. Stockton KA, Mengelsen K, Paratz JD, Kandiah D, Bennell KL. Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int. 2010;22:859–71.

34. Tomilinson PB, Joseph C, Angioi M. Effects of vitamin D supplementation on upper and lower body muscle strength levels in healthy individuals. A systematic review with meta-analysis. J Sci Med Sport. 2014;18(5):575–80.

35. Beaufort C, Buckfin C, Rabenda V, Gillaire S, Cavalier E, Sloman J, et al. The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2014;99:4336–435.

36. Von Hurst PR, Beck VL. Vitamin D and skeletal muscle function in athletes. Curr Opin Clin Nutr Metab Care. 2014;17:539–45.

37. Gregory SM, Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Moeckel-Cole S, et al. Changes in vitamin D are not associated with changes in cardiorespiratory function. Clin Med Res. 2013;2:68.

38. Movry DA, Costello MM, Heelan KA. Association among cardiorespiratory fitness, body fat, and bone marker measurements in young healthy females. J Am Osteopath Assoc. 2009;109(10):534–9.

39. Ardestani A, Barathe M, Mathur S, Clarkson P, Pescatoli LS, Hoffman HI, et al. Relation of vitamin D level to maximal oxygen uptake in adults. Am J Cardiol. 2011;107:1246–9.

40. Koundourakis NE, Androulakis NE, Malliarakis N, Margioris AN. Relation of vitamin D level to maximal oxygen uptake in adults. Am J Cardiol. 2011;107:1246–9.

41. Fitzgerald J, Peterson B, Warpeha J, Wilson P, Rhodes G, Ingraham S. Vitamin D status and VO2peak during a static treadmill graded exercise test in competitive ice hockey players. J Strength Cond Res. 2012;26(4):951–4.

42. Forney L, Earnest CC, Henagan T, Johnson L, Castleberry T, Stewart L. Vitamin D Status, Body Composition, and Fitness Measures in College-Aged Students. J Strength Cond Res. 2014;28:814–24.

43. Jastrzębski Z. Effect of vitamin D supplementation on the level of physical fitness and blood parameters of rowers during the 8-week high intensity training, Facicula Educ Fiz Sport. 2014;2:57–67.

44. Sugimoto H, Shirou Y. Diversity and substrate specificity in the structures of steroidalcyrogenic cytochrome P450 enzymes. Biol Pharm Bull. 2012;35:818–23.

45. D’Anton G, Lanfranconi F, Pellegrino MA, Brocca L, Adami R, Rossi R, et al. Skeletal muscle hypertrophy and structure and function of skeletal muscle fibres in male body builders. J Physiol. 2006;570(Pt 3):611–27.

46. Schoenfeld B. The mechanisms of muscle hypertrophy and their application to resistance training. J Strength Cond Res. 2010;24:2587–72.

47. Schoenfeld B. Does exercise-induced muscle damage play a role in skeletal muscle hypertrophy? J Strength Cond Res. 2012;26:1441–53.

48. Garcia LA, Ferrini MG, Norris KC, Arzana JN. 1,25(OH)2vitamin D3 enhances myogenic differentiation by modulating the expression of key angiogenic growth factors and angiogenic inhibitors in C2C12 skeletal muscle cells. J Steroid Biochem Mol Biol. 2013;138:131–11.

49. Garcia LA, King KK, Ferrini MG, Norris KC, Arzana JN. 1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myosin in C2C12 skeletal muscle cells. Endocrinology. 2011;152:2976–86.

50. Stratos I, Li Z, Herlyn P, Rotter R, Behrendt A-K, Mittmeyer T, et al. Vitamin D increases cellular turnover and functionally restores the skeletal muscle after crush injury in rats. Am J Pathol. 2013;182:805–904.

51. Lund D, Comelssen D. Enter the matrix: shape, signal and superhighway. Facicula Educ Fiz Sport. 2014;28:3200–1.

52. Bischoff-Hordegher M, Gudat F, Duerkmueller U, Theiler R, Stafelin H, et al. Identification of 1,25-dihydroxyvitamin D3 receptors in human skeletal muscle tissue. Histochim J. 2001;33:19–24.

53. Simpson R, Thomas G, Arnold A. Identification of 1,25-dihydroxyvitamin D3 receptors and activities in muscle. J Biol Chem. 1985;360:8882–91.

54. Hamilton B. Vitamin D and athletic performance: the potential role of muscle. Asian J Sports Med. 2011;2:11–19.

55. Stockton KA, Mengelsen K, Paratz JD, Kandiah D, Bennell KL.Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int. 2010;22:859–71.
57. Maura N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity*. J Clin Endocrinol Metab. 1998;83:1868–902.

58. Wehr E, Pliz S, Boehm B, Mazi W, Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf). 2010;73:240–8.

59. Pliz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B, et al. Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2011;43:223–5.

60. Kintun K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads*. Endocrinology 2004;145:317–324.

61. Blomberg Jensen M, Nielsen JE, Jørgensen R, Rasmussen-Madsen K, Dissing S. Non-genomic effects of vitamin D in human skeletal muscle. J Physiol. 2010;588:5482–507.

62. Blomberg Jensen M, Dissing S. Non-genomic effects of vitamin D in human skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7:271–7.

63. Urban RJ. Growth hormone and testosterone: Anabolic effects on body composition. Horm Res Pediatr. 2011;76:68–13.

64. Holick M, MacLaughlin J, Clark M, Holick S, Potts J, Anderson R, et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Am Assoc Adv Sci. 1982;210:203–05.

65. Webb AR, Who, what, where and when-influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol. 2006;26:17–25.

66. Gilchrest B. Sun exposure and vitamin D sufficiency. Am J Clin Nutr. 2008;88:570–7.

67. Lim HW, Gilchrest BA, Cooper KD, Bischoff-Ferrari HA, Rigèl DS, Cyr WH, et al. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol. 2005;52:869–76.

68. Wolkowetz D, Gilchrest BA. The vitamin D questions: how much do you need and how should you get it? J Am Acad Dermatol. 2006;54:301–17.

69. Holick MF. Sunlight “D”ilemma: Risk of skin cancer or bone disease and muscle weakness. Lancet 2001;6:4–6.

70. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol. 2003;8:1535–41.

71. Mithal A, Wahl DA, Bonjour JP, Burckhartt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807–20.

72. Walker N, Love TD, Baker DF, Haszard J, Edwards AS, et al. Knowledge and attitudes to vitamin D and sun exposure in elite New Zealand athletes: a cross-sectional study. J Int Soc Sports Nutr. 2014;11:47.

73. Matsuka LY, Wortsman J, Holmow BW. Use of topical sunscreen for the evaluation of regional vitamin D status. J Am Acad Dermatol. 1990;22:772–5.

74. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penso S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–64.

75. Holick M. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.

76. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006;84:694–7.

77. Logan VF, Gray AR, Peddie MC, Harper MJ, Houghton LA. Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95:1082–8.

78. Harris SS, Dawson-Hughes B. Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3. J Am Coll Nutr. 2002;21:357–62.

79. Post JL, Rich Ern JZ. Controversies in vitamin D recommendations and its possible roles in nonskeletal health issues. J Nutr Food Sci. 2015;5:5.

80. Ross AC, Taylor CL. Calcium Vitamin D: Valle HB Del; 2011.

81. Cannell J, Hollis B. Use of vitamin D in clinical practice. Altern Med Rev. 2008;13:6–20.

82. Heaney RP. Assessing vitamin D status. Curr Opin Clin Nutr Metab Care. 2011;14:440–44.

83. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842–56.

84. Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.

85. Holick MF. Vitamin D and bone health. Curr Opin Gastroenterol. 2012;28:139–50.

86. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:3065–6.

87. Barger-Lux MJ, Heaney RP, Dowell S, Chen TC, Holick MF. International original article article vitamin D and its major metabolites: Serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998;2:225–30.

88. Lappe J, Cullen D, Haynatzki G, Recker R, Ahlf R, Thompson K. Calcium and vitamin d supplementation decreases incidence of stress fractures in female navy recruits. J Bone Miner Res. 2008;23:741–9.

89. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimation of optimal vitamin D status. Osteoporos Int. 2005;16:713–6.

90. Heaney RP, Davies KM, Chen TC, Holick MF, Janet Barger-Lux M. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204–10.

91. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988;67:373–8.

92. Valuetha J, Domínguez D, Til L, González-Gross M, Drobnic F. High prevalence of vitamin D insufficiency among elite Spanish athletes the importance of outdoor training adaptation. Nutr Hosp. 2014;30:124–31.

93. Villacic D, Yi A, Jahn R, Kephart CJ, Charlton T, Gamradt SC, et al. Prevalence of Abnormal Vitamin D Levels Among Division I NCAA Athletics. Sports Health. 2014;6:340–7.

94. Constantini NW, Arieli R, Chodick G, Dubnov-Raz G. High prevalence of vitamin D insufficiency in athletes and dancers. Clin J Sport Med. 2010;20:368–8.

95. Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135:2795–98.

96. Van den Ouweland J, Fleuren H, Drabbe M, Suttorla H. Pharmacokinetics and safety issues of an accidental overdose of 2,000,000 IU of vitamin D3 in two nursing home patients: a case report. BMC Pharmacol Toxicol. 2014;15:57.

97. Suda T, Ueno Y, Fuji K, Shinko T, Vitamin D and bone. J Cell Biochem. 2003;88:259–65.

98. Zittermann A. Vitamin D and cardiovascular disease. Anticancer Res. 2014;34:4641–468.

99. Kerd PM. Vitamins D and K as pleiotropic nutrients: clinical importance to the skeletal and cardiovascular systems and preliminary evidence for synergy. Altern Med Rev. 2015;19:199–222.

100. Gundberg CM, Lind JB, Booth SL, Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Adv Nutr Am. 2012;3:149–57.

101. Muzuguchi M, Fujisawa R, Nara M, Nitta K, Kawano K. Fourier-Transform infrared spectroscopic study of Ca2+-binding to osteocalcin. Calcif Tissue Int. 2001;69:337–42.

102. Fitzpatrick TB, Basset GJ, Borel P, Canari F, DeltaPenna D, Fraser PD, et al. Vitamin D deficiencies in humans: can plant science help? Plant Cell 2012;24:395–414.

103. Binkley NC, Krueger DC, Kawana MH, Engleke JA, Chappell RJ, Sutton JW. A high phyloquinonme intake is required to achieve maximal osteocalcin γ-carboxylation. Am J Clin Nutr. 2002;76:1055–60.

104. Akiyama Y, Hara K, Tajima T, Murata S, Morita I. Effect of vitamin K2 (menatetrenone) on osteocalcin-like cell formation in mouse bone marrow cultures. Eur J Pharmacol. 1994;263:181–5.
110. Akiyama Y, Hara K, Kobayashi M, Tomiuga T, Nakamura T. Inhibitory Effect of Vitamin K2 (Menatetrenone) on Bone Resorption in Ovariectomized Rats. A Histomorphometric and Dual Energy X-Ray Absorptiometric Study. The Japanese Journal of Pharmacology. 1999;80(1):67–74.

111. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999;69:74–9.

112. Masterjohn C. Vitamin D toxicity redefined: vitamin K and the molecular mechanism. Med Hypotheses. 2007;68:1026–34.

113. El Asmar MS, Naoum JJ, Arbid EJ. Vitamin k dependent proteins and the role of vitamin k2 in the modulation of vascular calcification: a review. Oman Med J. 2014;29:172–7.

114. Hamidi MS, Cheung AM. Vitamin K and musculoskeletal health in postmenopausal women. Mol Nutr Food Res. 2014;58:1647–57.

115. Iwamoto J. Vitamin K2 therapy for postmenopausal osteoporosis. Nutrients. 2014;6:1971–80.

116. Murakami K, Yamanaka N, Ohnishi K, Fukayama M, Yoshino M. Inhibition of angiotensin I converting enzyme by subtilisin NAT (nattokinase) in natto, a Japanese traditional fermented food. Food Funct. 2012;3:674–8.

117. Dowd P, Hershline R, Ham SW, Naganathan S. Mechanism of action of vitamin K. Nat Prod Rep. 1994;11:251–64.

118. Fusaro M, Crepaldi G, Maggi S, Galli F, D'Angelo A, Calò L, et al. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J Endocrinol Invest. 2011;34:317–23.

119. Konakion®. Konakion®. 2010. p. 1–6.

120. Craciun AM, Wolf J, Knappen MH, Brouns F, Vermeer C. Improved bone metabolism in female elite athletes after vitamin K supplementation. Int J Sports Med. 1998;19:479–84.

121. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr. 2006;84:671–672.